4 recruiting, 3 active not recruiting, 3 completed, 2 terminated. 12 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 4, Active not recruiting 3, Completed 3, Terminated 2 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow Myeloproliferative Neoplasms: new trials by email Literature Review of Myeloproliferative Neoplasms trials Research Report on Myeloproliferative Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-10-30 |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms INCA035784 - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 120 | 2025-10-01 | 2026-08-06 |
| Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation Ivosidenib, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Recruiting | University of Chicago | 18 | 2024-09-19 | 2026-09-01 |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms INCB160058, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Active not recruiting | Incyte Corporation | 37 | 2024-08-08 | 2026-08-12 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms INCA033989, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 290 | 2023-12-04 | 2026-04-17 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms INCA033989, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Active not recruiting | Incyte Corporation | 160 | 2023-09-25 | 2026-08-10 |
| A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms VAC85135, Ipilimumab - Myeloproliferative Neoplasms | Phase 1 | Completed | Janssen Research & Development, LLC | 14 | 2022-07-21 | 2025-07-20 |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Jaktinib, azacitidine - Myelodysplastic Syndromes, Myeloproliferative Neoplasms | Phase 1 / Phase 2 | Terminated | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 1 | 2021-09-30 | 2022-12-01 |
| A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Ipilimumab, CD25hi Treg depleted DLI - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 25 | 2019-07-10 | 2026-01-05 |
| A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms TQ05105 - Myeloproliferative Neoplasms | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 79 | 2018-11-20 | 2026-06-03 |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Pemigatinib, Gemcitabine, Pembrolizumab - Lung Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 201 | 2015-02-27 | 2023-01-06 |
| Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Ruxolitinib, Decitabine - Myeloproliferative Neoplasms | Phase 1 / Phase 2 | Completed | John Mascarenhas | 49 | 2014-02-01 | 2019-02-28 |
Myeloproliferative Disorders (12) · Primary Myelofibrosis (7) · Thrombocythemia, Essential (4) · Myelodysplastic Syndromes (2) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lung Neoplasms (1) · Multiple Myeloma (1) · Polycythemia Vera (1) · Stomach Neoplasms (1)
Bone Marrow Diseases (12) · Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Hemorrhagic Disorders (5) · Blood Coagulation Disorders (4) · Blood Platelet Disorders (4) · Thrombocytosis (4) · Neoplasms (3) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Adenocarcinoma (1) · Blood Protein Disorders (1) · Bone Marrow Neoplasms (1) · Breast Diseases (1) · Carcinoma (1)
ruxolitinib (4) · Ipilimumab (2) · Azacitidine (1) · Cisplatin (1) · Decitabine (1) · Docetaxel (1) · Gemcitabine (1) · Trastuzumab (1) · ivosidenib (1) · pembrolizumab (1) · pemigatinib (1)
Incyte Corporation (6) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dana-Farber Cancer Institute (1) · Janssen Research & Development, LLC (1) · John Mascarenhas (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · University of Chicago (1)
United States (9) · Germany (4) · Italy (4) · United Kingdom (4) · Australia (3) · Canada (3) · France (3) · Belgium (2) · China (2) · Denmark (2) · Japan (2) · Spain (2) · Norway (1) · South Korea (1) · Switzerland (1)
Anand Patel (1) · John Koreth, MD (1) · John Mascarenhas, MD (1) · Ronald Hoffman, MD (1)
PMID 33104796, PMID 34951522, PMID 35176457
P01CA108671 (1), P01CA229092 (1)